Pilot study of H2 therapy in Parkinson's disease: A randomized double-blind placebo-controlled trial

Movement Disorders

Volumn 28, Issue 6, 2013, Pages 836-839

  Yoritaka, Asako ^a,b   Takanashi, Masashi ^a   Hirayama, Masaaki ^c   Nakahara, Toshiki ^a   Ohta, Shigeo ^d   Hattori, Nobutaka ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Juntendo University Hospital   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Hydrogen; Oxidative stress; Parkinson's disease; Randomized double blind placebo controlled trial

Indexed keywords

DRINKING WATER; HYDROGEN; IRON; LEVODOPA; LIPID; PLACEBO;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; FEMALE; FLUID THERAPY; HUMAN; LIPID PEROXIDATION; MALE; OXIDATIVE STRESS; PARKINSON DISEASE; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THERAPY EFFECT; UNIFIED PARKINSON DISEASE RATING SCALE;

AGED; ANTIPARKINSON AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDROGEN; JAPAN; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; PILOT PROJECTS; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; WATER;

EID: 84879602817     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25375     Document Type: Article

References (11)

1. Dexter DT, Wells FR, Agid F, Agid Y, Lees AJ, Jenner P, Marsden CD. Increased nigral iron content in postmortem Parkinsonian brain. Lancet 1987;8569:1219-1220.
2. Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman ER, Mizuno Y. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci U S A 1996;93:2696-2701.
3. Ohsawa I, Ishikawa M, Takahashi K, et al. Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals. Nat Med 2007;13:688-694.
4. Ohta S. Molecular hydrogen is a novel antioxidant to efficiently reduce oxidative stress with potential for the improvement of mitochondrial diseases. Biochim Biophys Acta 2012;1820:586-594.
5. Fujita K, Seike T, Yutsudo N, et al. Hydrogen in drinking water reduces dopaminergic neuronal loss in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mouse model of Parkinson's disease [serial online]. PLoS One 2009;30:e7247.
6. Fu Y, Ito M, Fujita Y, et al. Molecular hydrogen is protective against 6-hydroxydopamine-induced nigrostriatal degeneration in a rat model of Parkinson's disease. Neurosci Lett 2009;453:81-85.
7. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
8. Nagata K, Nakashima-Kamimura N, Mikami T, Ohsawa I, Ohta S. Consumption of molecular hydrogen prevents the stress-induced impairments in hippocampus-dependent learning tasks during chronic physical restraint in mice. Neuropsychopharmacology 2009;34:501-508.
9. Shimouchi A, Nose K, Shirai M, Kondo T. Estimation of molecular hydrogen consumption in the human whole body after the ingestion of hydrogen-rich water. Adv Exp Med Biol 2012;737:245-250.
10. Ohno K, Ito M, Ichihara M, Ito M. Molecular hydrogen as an emerging therapeutic medical gas for neurodegenerative and other disease [serial online]. Oxid Med Cell Longev 2012;2012:353152.
11. Fox SH, Katzenschlager R, Lim SY, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: treatments for the motor symptoms of Parkinson's disease. Mov Disord 2011;26: S2-S41.